Literature DB >> 2944209

Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.

J E Pennington, G B Pier, J C Sadoff, G J Small.   

Abstract

The unusually high mortality associated with Pseudomonas aeruginosa pneumonia has provided an incentive for the development of immunologic strategies for preventing or treating this infection. A guinea pig model of experimental P. aeruginosa pneumonia was employed to determine prophylactic efficacy of active immunization with a detoxified lipopolysaccharide vaccine; efficacy of passive immune therapy utilizing a new hyperimmune immunoglobulin G preparation enriched for antibodies to P. aeruginosa immunotypes 1, 2, 4, and 6; and efficacy of active and passive immunization against the mucoid exopolysaccharide antigen associated with mucoid strains of P. aeruginosa. Each of these immunologic methods provided an element of protection against P. aeruginosa pneumonia.

Entities:  

Mesh：

Substances：

Year:  1986        PMID： 2944209     DOI： 10.1093/clinids/8.supplement_4.s426

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN： 0162-0886


  9 in total

1.  Therapy of pseudomonal infections.

Authors:  A Kumar
Journal:  Indian J Pediatr       Date:  1987 Jul-Aug       Impact factor: 1.967

2.  Tumor Necrosis Factor α Reduces SNAP29 Dependent Autolysosome Formation to Increase Prion Protein Level and Promote Tumor Cell Migration.

Authors:  Huan Li; Ren Wang; Ze Yu; Run Shi; Jie Zhang; Shanshan Gao; Ming Shao; Shuzhong Cui; Zhenxing Gao; Jiang Xu; Man-Sun Sy; Chaoyang Li
Journal:  Virol Sin       Date:  2020-11-25       Impact factor: 4.327

3.  [Prevention of gram-negative and gram-positive infections with 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection with intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

Authors:  M S Collins; R F Hector; R E Roby; A A Edwards; D K Ladehoff; J H Dorsey
Journal:  Infection       Date:  1987       Impact factor: 3.553

4.  [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].

Authors:  J E Pennington; G B Pier
Journal:  Infection       Date:  1987       Impact factor: 3.553

5.  [Pseudomonas aeruginosa immunoglobulin in experimental pneumonia].

Authors:  J E Pennington; G B Pier
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

6.  Binding to and opsonophagocytic activity of O-antigen-specific monoclonal antibodies against encapsulated and nonencapsulated Klebsiella pneumoniae serotype O1 strains.

Authors:  T K Held; N R Jendrike; T Rukavina; R Podschun; M Trautmann
Journal:  Infect Immun       Date:  2000-05       Impact factor: 3.441

7.  Pseudomonas aeruginosa-induced lung and pleural injury in sheep. Differential protective effect of circulating versus alveolar immunoglobulin G antibody.

Authors:  J F Pittet; M A Matthay; G Pier; M Grady; J P Wiener-Kronish
Journal:  J Clin Invest       Date:  1993-09       Impact factor: 14.808

8.  [Prevention of gram-negative and gram-positive infections using 3 intravenous immunoglobulin preparations and therapy of experimental polymicrobial burn infection using intravenous Pseudomonas immunoglobulin G and ciprofloxacin in an animal model].

Authors:  M S Collins; R F Hector; R E Roby; A A Edwards; D K Ladehoff; J H Dorsey
Journal:  Infection       Date:  1987 Jan-Feb       Impact factor: 3.553

Review 9.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.